未找到相关数据
The Talazoparib Beyond BRCA (TBB) trial: A phase II clinical trial of talazoparib (BMN 673) in BRCA1 and BRCA2 wild-type patients with (i) advanced triple negative breast cancer (TNBC) and homologous recombination deficiency (HRD) as assessed by myriad genetics HRD assay, and (ii) advanced HER2-negative breast cancer (BC) with either a germline or somatic mutation in homologous recombination (HR) pathway genes
被引：3
作者：
Afghahi, A.
[1
]
Chang, P-J
[1
]
Ford, J. M.
[1
]
Telli, M. L.
[1
]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
来源：
关键词：
D O I：
10.1158/1538-7445.SABCS15-OT2-05-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-05-04
引用
收藏
页数：2
相关论文